Early-stage Breast Cancer
Conditions
Keywords
Filgrastim, Pegfilgrastim
Brief summary
REaCT-5G will compare bone pain from a single dose of Pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy.
Detailed description
The use of granulocyte colony-stimulating factors (G-CSF) significantly reduces febrile neutropenia (FN) risk and has helped maintain dose intensity and dose density when treating breast cancer with chemotherapy. This is crucial as survival outcomes are significantly impaired if dose intensity are reduced. National and international guidelines recommend the use of G-CSF as primary prophylaxis with most commonly used breast cancer chemotherapy regimens. Filgrastim (FIL) as a G-CSF that has been in use since the early 90s. Pegfilgrastim (PEG) is a long-acting, pegylated version of FIL that requires only one injection per chemotherapy cycle instead of daily FIL injections for 5 to 10 days per cycle. PEG and FIL both come at the potential cost of bone pain, the most common side effect. G-CSF related bone pain is often severe, leading to refusal or cancellation of G-CSF and early discontinuation of chemotherapy. We propose to perform a pragmatic, multicenter, open-label, randomized clinical trial to compare bone pain experienced by patients receiving either PEG or 5-day-FIL with neoadjuvant or adjuvant chemotherapy.
Interventions
DRUGFilgrastim
Receive filgrastim subcutaneous injection once daily for five consecutive days starting 24-72 hours after chemotherapy
DRUGPegfilgrastim
Receive pegfilgrastim as a single dose subcutaneous injection 24-72 hours after chemotherapy
Sponsors
Ottawa Hospital Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with early-stage or locally-advanced breast cancer receiving neoadjuvant or adjuvant chemotherapy requiring primary febrile neutropenia prophylaxis with G-CSF * Able to provide verbal consent * Able to complete questionnaires in English or French
Exclusion criteria
* No access to pegfilgrastim or filgrastim prior to randomization * Metastatic cancer * Known hypersensitivity to filgrastim or pegfilgrastim or one of its components
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bone pain | 5 days after first G-CSF injection | Bone pain over the first 5 days after the administration of G-CSF. The total measure of bone pain over the five days will be summarized by the area under the curve (AUC) based on a patient's daily pain score, starting after the first dose of G-CSF injection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-related hospitalizations | 2.5 years after study initiation | Number of times participants have a treatment-related hospitalization |
| Incidence of chemotherapy alteration | 2.5 years after study initiation | Number of times participants have a chemotherapy alteration including: dose delay, reduction and/or discontinuation |
| Incidence of chemotherapy-related mortality | 2.5 years after study initiation | Number of times there is a chemotherapy-related mortality |
| Rate of G-CSF compliance as prescribed | 2.5 years after study initiation | Number of times there is a G-CSF compliance |
| Incidence of Febrile Neutropenia | 2.5 years after study initiation | Number of times participants have Febrile neutropenia during chemotherapy treatment |
| HR-QoL | 2.5 years after study initiation | HR-QoL based on EQ-5D-5L |
| Cost-effectiveness | 2.5 years after study initiation | Cost differences associated with prescribing Filgrastim and Pegfilgrastim |
| Patient G-CSF preference | 2.5 years after study initiation | To survey patient preference in selection of G-CSF treatment before and after undergoing chemotherapy and G-CSF treatment |
| Study feasibility | 1 year after study initiation | Interim analysis/feasibility. After the first year of study initiation, if study recruitment is less than 30% at one year (70 patients), or if there are unanticipated safety issues, a review of study conduct will be performed to consider stopping the study unless there are unexpected or exceptional reasons, or in the case of low recruitment, there is a plan to boost recruitment efforts |
| Differences in healthcare resource utilization | 2.5 years after study initiation | Differences in healthcare resource utilization: number of emergency room visits, number of planned/unplanned provider clinic visits (including stretcher bay), patient-reported phone calls or email to patient support line or provider, and additional medication use or management strategies related to G-CSF side effects or efficacy |
Countries
Canada
Outcome results
None listed